Use of biomarkers in treatment with bifidobacteria
AssigneeInternational N&H Denmark Aps
InventorsNiels Christensen, Henrik Max Jensen, Henna-Maria Kailanto, Christian Clement Yde
Life of this patent
Estimating the term…
Abstract
This invention relates to a method of identifying a subject having an increased probability of having a beneficial clinical response to administration of a bacterial strain of the genus Bifidobacterium or a mixture of two or more strains thereof to said subject, by measuring the level of some specific biomarkers in said subject.
Claims18
A method of identifying a subject having an increased probability of having a beneficial clinical response to administration of a bacterial strain of the genus Bifidobacterium or a mixture of two or more strains thereof, the method comprising the steps of,
- i. measuring the level of at least one of the following biomarkers:
- hPAI1 Total;
- a bile acid selected from GLCA, LCA, Iso-LCA, and DCA;
- a phospholipid selected from phosphatidylcholine(36:4), phosphatidylcholine(32:1), phosphatidylethanolamine(38:4), phosphatidylethanolamine(36:4), and phosphatidylinositol(40:4);
- a bacteria selected from Coprococcus, Ruminococcus, Akkermansia, Aminipila butyrica, Unclassified Clostridiales-Incertae Sedis XIII, and Eubacterium coprostanoligenes;
- Pimelic acid and Azelaic acid;
- in a biological sample obtained from said subject, and/or the daily activity of the subject in steps or corresponding physical activity;
- and
- ii. comparing said level to a threshold value,
- wherein when the measured level of at least one of the biomarkers is higher than said threshold value, the subject is identified as having said increased probability.
The method according to any one of the preceding claims, wherein said bacterial strain of the genus Bifidobacterium or a mixture of two or more said strains thereof if of the species Bifidobacterium animalis, preferably of the species Bifidobacterium animalis subsp. Lactis, such as the bacterial strain of the species Bifidobacterium animalis subsp. Lactis strain B420.
The method according to any one of the preceding claims, wherein the measured level of hPAI1 Total in the biological sample obtained from said subject is above 48245 pg/ml.
The method according to any one of the preceding claims, wherein the daily activity of the subject in steps is above 7000, or corresponding physical activity.
Use of a bacterial strain of the genus Bifidobacterium or a mixture of two or more strains thereof for at least one of managing weight, such as, lowering BMI, lowering blood glucose level, reducing body fat, controlling weight gain, inducing weight loss, lowering body fat mass, lowering mesenteric fat mass, lowering trunk fat mass and/or decreasing android fat mass, treating diabetes (preferably but not exclusively Type 2 diabetes), treating impaired glucose tolerance, normalizing insulin sensitivity, increasing fed insulin secretion, decreasing fasted insulin secretion, improving glucose tolerance, treating obesity, lowering tissue inflammation (particularly, although not exclusively, muscle tissue inflammation, liver tissue inflammation and/or adipose tissue inflammation), treating hepatitis, treating myositis, treating cardiovascular disease and treating metabolic syndrome, in a subject, wherein said subject has been identified as having an increased probability of having a beneficial clinical response to administration of said bacterial strain of the genus Bifidobacterium or a mixture of two or more strains thereof, by,
- i. measuring the level of at least one of the following biomarkers:
- hPAI1 Total;
- a bile acid selected from GLCA, LCA, Iso-LCA, and DCA;
- a phospholipid selected from phosphatidylcholine(36:4), phosphatidylcholine(32:1), phosphatidylethanolamine(38:4), phosphatidylethanolamine(36:4), and phosphatidylinositol(40:4);
- a bacteria selected from Coprococcus, Ruminococcus, Akkermansia, Aminipila butyrica, Unclassified Clostridiales-Incertae Sedis XIII, and Eubacterium coprostanoligenes;
- Pimelic acid and Azelaic acid;
- in a biological sample obtained from said subject, and/or the daily activity of the subject in steps;
- and
- ii. comparing said level to a threshold value,
- wherein when the measured level of at least one of the biomarkers is higher than said threshold value, the subject is identified as having said increased probability.
Bacterial strain of the genus Bifidobacterium or a mixture of two or more strains thereof for use in managing weight, such as, lowering BMI, lowering blood glucose level, reducing body fat, controlling weight gain, inducing weight loss, lowering body fat mass, lowering mesenteric fat mass, lowering trunk fat mass and/or decreasing android fat mass, treating diabetes (preferably but not exclusively Type 2 diabetes), treating impaired glucose tolerance, normalizing insulin sensitivity, increasing fed insulin secretion, decreasing fasted insulin secretion, improving glucose tolerance, treating obesity, lowering tissue inflammation (particularly, although not exclusively, muscle tissue inflammation, liver tissue inflammation and/or adipose tissue inflammation), treating hepatitis, treating myositis, treating cardiovascular disease and treating metabolic syndrome, in a subject, wherein said subject has been identified as having an increased probability of having a beneficial clinical response to administration of said bacterial strain of the genus Bifidobacterium or a mixture of two or more strains thereof, by,
- i. measuring the level of at least one of the following biomarkers:
- hPAI1 Total;
- a bile acid selected from GLCA, LCA, Iso-LCA, and DCA;
- a phospholipid selected from phosphatidylcholine(36:4), phosphatidylcholine(32:1), phosphatidylethanolamine(38:4), phosphatidylethanolamine(36:4), and phosphatidylinositol(40:4);
- a bacteria selected from Coprococcus, Ruminococcus, Akkermansia, Aminipila butyrica, Unclassified Clostridiales-Incertae Sedis XIII, and Eubacterium coprostanoligenes;
- Pimelic acid and Azelaic acid;
- in a biological sample obtained from said subject, and/or the daily activity of the subject in steps;
- and
- ii. comparing said level to a threshold value,
- wherein when the measured level of at least one of the biomarkers is higher than said threshold value, the subject is identified as having said increased probability.
Method of managing weight, such as, lowering BMI, lowering blood glucose level, reducing body fat, controlling weight gain, inducing weight loss, lowering body fat mass, lowering mesenteric fat mass, lowering trunk fat mass and/or decreasing android fat mass, treating diabetes (preferably but not exclusively Type 2 diabetes), treating impaired glucose tolerance, normalizing insulin sensitivity, increasing fed insulin secretion, decreasing fasted insulin secretion, improving glucose tolerance, treating obesity, lowering tissue inflammation (particularly, although not exclusively, muscle tissue inflammation, liver tissue inflammation and/or adipose tissue inflammation), treating hepatitis, treating myositis, treating cardiovascular disease and treating metabolic syndrome, in a subject in need thereof, said method comprising administering a bacterial strain of the genus Bifidobacterium or a mixture of two or more strains thereof to said subject, wherein said subject has been identified as having an increased probability of having a beneficial clinical response to the administration of said bacterial strain of the genus Bifidobacterium or a mixture of two or more strains thereof, by,
- i. measuring the level of at least one of the following biomarkers:
- hPAI1 Total;
- a bile acid selected from GLCA, LCA, Iso-LCA, and DCA;
- a phospholipid selected from phosphatidylcholine(36:4), phosphatidylcholine(32:1), phosphatidylethanolamine(38:4), phosphatidylethanolamine(36:4), and phosphatidylinositol(40:4);
- a bacteria selected from Coprococcus, Ruminococcus, Akkermansia, Aminipila butyrica, Unclassified Clostridiales-Incertae Sedis XIII, and Eubacterium coprostanoligenes;
- Pimelic acid and Azelaic acid;
- in a biological sample obtained from said subject, and/or the daily activity of the subject in steps;
- and
- ii. comparing said level to a threshold value,
- wherein when the measured level of at least one of the biomarkers is higher than said threshold value, the subject is identified as having said increased probability.
A method of managing weight, such as, lowering BMI, lowering blood glucose level, reducing body fat, controlling weight gain, inducing weight loss, lowering body fat mass, lowering mesenteric fat mass, lowering trunk fat mass and/or decreasing android fat mass, treating diabetes (preferably but not exclusively Type 2 diabetes), treating impaired glucose tolerance, normalizing insulin sensitivity, increasing fed insulin secretion, decreasing fasted insulin secretion, improving glucose tolerance, treating obesity, lowering tissue inflammation (particularly, although not exclusively, muscle tissue inflammation, liver tissue inflammation and/or adipose tissue inflammation), treating hepatitis, treating myositis, treating cardiovascular disease and treating metabolic syndrome, in a subject in need thereof, said method comprising
- i. Prescribing to the subject a daily personal activity of more than 7000 steps, or corresponding physical activity;
- and
- ii. administering a bacterial strain of the genus Bifidobacterium or a mixture of two or more strains thereof to the subject having obtained the activity under i), which subject has an increased probability of having a beneficial clinical response to the administration of said bacterial strain of the genus Bifidobacterium or a mixture of two or more strains thereof.
Dependencies are inferred from the claim text.